Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30th Annual Congress
Genascence Corporation, a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy using technology discovered at the University of Florida, announced that data from the Phase 1 clinical trial of GNSC-001 for the treatment of osteoarthritis (OA) demonstrated that it was safe and well tolerated.
Dr. Barry Byrne Named Innovator of the Year
The annual event honored Dr. Barry Byrne as Innovator of the Year for his contributions to gene therapy and highlighted six teams of inventors for their Inventions of the Year.
Myrtelle Enters Into a Worldwide Exclusive License Agreement With Rescue Hearing To Develop and Commercialize Gene Therapy for the Treatment of Hearing Loss
Myrtelle Inc., a clinical stage gene therapy company focused on developing transformative treatments for rare genetic diseases, today announced that it has entered into a worldwide exclusive licensing agreement with UF Innovate | Accelerate at The Hub alum Rescue Hearing Inc. (RHI) to develop a novel gene therapy for DFNB8 genetic hearing loss.
AavantiBio Furthers Strategic Partnership With University of Florida To Research and Develop Next Generation Gene Therapy Capsids
UF startup and UF Innovate | The Hub resident AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, announced it is partnering with the University of Florida to research and develop next generation gene therapy capsids with the goal of creating safer, more effective, and tissue specific gene therapies.
AGTC: The New Leader in Ocular Gene Therapy With Sue Washer
Sue Washer, president and CEO of Applied Genetic Technologies Corporation (AGTC), discusses ocular gene therapy with the Eye Care Insider podcast host Joshua Mali, MD.
AavantiBio and Resilience Announce Strategic Collaboration for Gene Therapy Development and Manufacturing
UF startup and UF Innovate | The Hub resident AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, and National Resilience, Inc. (Resilience), a company building the world’s most advanced biopharmaceutical manufacturing ecosystem and who recently acquired UF startup and UF Innovate | Sid Martin Biotech alum Ology Bioservices, announced a strategic collaboration to support the development and manufacturing of AavantiBio’s pipeline of therapies, including its lead program in Friedreich’s Ataxia (FA).
Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthritis
Genascence Corporation, a clinical-stage biotechnology company developing life-changing gene therapy products for prevalent musculoskeletal diseases, announced that dosing across all three cohorts has been completed in Phase 1 clinical trial of GNSC-001 for the treatment of osteoarthritis (OA).
Parent Project Muscular Dystrophy Awards $348,891 Grant to University of Florida Wellstone Center
Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy, awarded the University of Florida Wellstone Muscular Dystrophy Cooperative Center a grant for $348,891.
University of Florida Health Ophthalmology Researcher Awarded Prestigious Prize for Pioneering Work
University of Florida Health ophthalmology researcher William W. Hauswirth, Ph.D., whose long and distinguished career includes developing and testing treatments for multiple forms of genetic blindness, is among the scientists being recognized for their pioneering work to eradicate vision loss.
Dr. Barry Byrne Receives “See the Light” Award From the Mathew Forbes Romer Foundation
For families facing a devastating diagnosis of pediatric neurodegenerative genetic disease, Barry Byrne, M.D., Ph.D., provides a sense of hope and possibility.... Read More
